Stephen K. Burley

Prof. Stephen K. Burley
Born	1958 (age 57–58)
Institutions	Rutgers University Lilly Research Laboratories Rockefeller University Howard Hughes Medical Institute
Alma mater	University of Western Ontario University of Oxford Harvard Medical School
Thesis	Molecular arrangement in viruses studied by X-ray and neutron scattering and other physical techniques (1983)
Doctoral advisor	Dr. Andrew Miller

Stephen Kevin Burley is a British-born scientist, naturalized in both Canada and the United States, specializing in oncology and structural biology. He is a Distinguished Professor in the Department of Chemistry and Chemical Biology at Rutgers University. Burley directs the RCSB Protein Data Bank (a member of the Worldwide Protein Data Bank) and the Center for Integrative Proteomics Research

Career

Burley has a Bachelor in physics from the University of Western Ontario^[1] and is D.Phil from Oxford University, England in Molecular Biophysics as a Rhodes scholar.^[2] Burley has an M.D. from Harvard Medical School.

He worked with Gregory A. Petsko and William N. Lipscomb at MIT and Harvard. He was faculty at Howard Hughes Medical Institute and Rockefeller University. Burley co-founded Prospect Genomics, Inc,^[3] a computational genomics pharma. He was Chief Scientific Officer of SGX Pharmaceuticals after it acquired Prospect. SGX was in turn merged with Eli Lilly in 2008 where Burley was a Distinguished Lilly Research Scholar in Lilly Research Laboratories^[4]

In 2012 Burley joined Rutgers ^[5] as Director of the Center for Integrative Proteomics Research and became director of the PDB in 2014, succeeding Prof. Helen Berman^[6]

Honors and awards

Fellow of the Royal Society of Canada (elected 1995)

References

This article is issued from Wikipedia - version of the 6/12/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.